Cure Clinic Covid

A trusted NHS partner providing FREE COVID-19 Lateral Flow Device Tests to those that need them*
*Must meet eligibility criteria, view HERE

Established over 60 years ago, Broadway Pharmacy with Cure Clinics has been providing award winning healthcare in the heart of our community for over 60 years. With a team of highly qualified pharmacist clinicians, technicians and advisors we work hard to care for you and your family.

Complete the form to receive your FREE Covid test kit

Date of Birth

You confirm the named person above qualifies as eligible for this free service as per the NICE guidelines, and is a patient registered with a GP practice in England. Am I Eligible?

Keep me up to date with Broadway Pharmacy with Cure Clinics (H & A K Fletcher Ltd) patient registrations, range of services, products, news and events via email. SMS, telephone and post

By registering for our service you confirm that we are authorised to access your National Care Records in order to assess your eligibility to receive this service.

By ticking this box you confirm that you have read, understood and agree to our Terms and Conditions, Privacy Policy and Cookies Policy

Test yourself this autumn and winter period

This autumn and winter the NHS want all eligible at risk patients to have access to COVID-19 tests to enable prompt testing at home should symptoms present and allow an informed clinical assessment to determine if recommended COVID-19 treatments are appropriate.
Whilst access to these tests will be available by walk-in collection from participating pharmacies, the discontinuation of the service via GOV.UK or by calling NHS 119 will make this difficult for many. We are providing a similar service for those that are not able to collect in person.

Our Process

Three
simple steps

In collaboration with the NHS, we provide FREE of CHARGE COVID-19 LFD tests to all at risk patients who are registered with GP practices across England.

Eligibility

Check if you are eligible to place an order. If you have not already been notified by the NHS, please review this LINK to confirm you are eligible before proceeding

Fill out the form

Provide us with your details by completing this form and confirm your eligibility in your declaration

COVID-19 LFD Test Kit Dispatch

Upon receiving your form, we will review and dispatch within 24 hours using Royal Mail’s 48hr postage service

NHS advice is that all eligible patients should have a pack of 5 tests so that testing can immediately commence should symptoms develop. Whilst we will monitor the frequency of orders all patients place, we encourage you to also ensure you always have a pack of 5 tests in your possession.

Providing NHS COVID-19 & Flu vaccinations
across the North West of England

When you visit one of our Lancashire Vaccination Centres you can be sure that we have taken every necessary step to keep you safe while providing an efficient service.
Our team of experienced, fully qualified healthcare professionals are dedicated to providing the highest quality care possible while delivering NHS vaccinations.

Find out more

Testimonial

What Our Patients Say

We have a 4.5/5 star review rating on Google. We're a dedicated local pharmacy that is now proud to serve the vulnerable with Free Covid-19 tests nationwide.

"I was struggling to get a hold of some regular medication on private prescription due to a shortage. Contacted many pharmacies for delivery and Broadway came through for me especially thanks to Huzaifa. Service was fast and communication over phone/email very good. Medication was in stock and sent to me next day in the post."

Matt Brett

Patient

"Wow. I was sent to pick up a prescription and I had to ask if this was a pharmacy as it looked more like a high end Selfridges type shop/spa. What a breath of fresh air to see a pharmacy that doesn’t look like a war zone. Such a lovely atmosphere with excellent customer service. Absolutely Amazing!"

Zach Khan

Patient

"This review is to give a special recognition to Huzaifah, it honestly puts me at ease when I know he is dealing with any issues of my son’s medication.
Thanks a lot for your patience in dealing with me and for all your help"

Nela k

Patient

"Excellent service from all the team. Mark & Sarah have gone above & beyond with care , kindness & support when I needed advice & urgent medication.The pharmacists liaise with your Gp if there is something you need help with & they genuinely care for patients / customers . Many thanks to all the team at Broadway Pharmacy ."

Wendy Watt

Patient

"Been going here for the last 3 years and service has been fantastic every time. Only once was medication out of stock and was quickly back in the same afternoon. Staff inside always very knowledgeable and friendly. Great variety and quantity of products."

Andrew Mortimer

Patient

Regular Covid-19 testing and vaccination

Ensuring the health and safety of those most at risk in our community.

Due to the success of the COVID-19 vaccination programme life, for most of us has largely returned to normal following the pandemic, however for a small number of people, the risk of serious illness from COVID-19 remains.

Promoting prevention and protection within our community remains our main priority. For those whose weakened immune system means they are eligible for treatment for COVID-19, Test yourself this Autumn and Winter.

Additional recommendations for those most at risk are:

Ensuring you have had all the vaccines you are eligible for
Avoid contact with anyone with COVID-19 symptoms
Keep your home well ventilated, especially when you have visitors
Consider adopting social distancing principles
Consider wearing a mask in crowded public spaces

For more info on guidance please visit this link click HERE

Phone

For direct assistance, please call us Monday to Friday, 8:30 AM - 6:00 PM, Saturday, 8:30 AM - 5:00 PM, and Sunday, 10:00 AM - 1:00 PM.

01772 717 574

Email

For email inquiries or questions, please reach out to us at the following address.

contact@broadway-pharmacy.co.uk

Location

331 Garstang Road, Fulwood, Preston,
PR2 9UP, UK.

BROADWAY PHARMACY LATERAL FLOW TEST TERMS AND CONDITIONS

1. ABOUT BROADWAY PHARMACY

1.1. Broadway Pharmacy ("we"/”us”/”our”) is the trading name of H. & A.K. Fletcher Limited. We are a private limited company incorporated in England and Wales under company number 01292679. Our registered office at 331 Garstang Rd, Fulwood, Preston, Lancashire, PR2 9UP, England, which is also the location of our pharmacy.

1.2. We and our pharmacists are registered with, and regulated by, the General Pharmaceutical Council (“GPhC”). Our GPhC registration number is 1035138.

1.3. You can contact us in relation to these Terms via email at contact@broadway-pharmacy.co.uk, by telephone on 01772 717 574 or otherwise by writing to us at our registered office address.

2. THESE TERMS AND CONDITIONS

2.1. These Terms and Conditions (“Terms”) apply to our Covid-19 Lateral Flow Device (“LFD”) online delivery service (“Service”), which we have put in place to support individuals who are at risk of becoming seriously ill should they contract Covid-19.

2.2. The objective of our Service is to offer eligible (see clause 4, below), at risk patients, to access LFD tests from their home, without the need to visit their local pharmacy. We have launched the Service in the context of the UK Government’s scaling back of the accessibility of LFDs via the www.gov.uk website, placing responsibility for the same with local pharmacies.

2.3. Our Service is available via our website: https://broadway-pharmacy.co.uk/ (“Website”). We also have a walk-in / collection facility during our pharmacy opening hours (as set out on our Website) and eligible patients can instead visit their local pharmacy to receive the Service.

2.4. These Terms contain important information regarding our Service including, in particular, information regarding who is eligible to receive the Services (clause 4), how delivery of the LFDs takes place (clause 6) and testing and positive results (clause 7).

2.5. There is no LFD or delivery charge associated with the Service, which is provided free of charge.

3. YOUR PRIVACY

3.1. Your privacy is our priority. You’ll find everything you need to know about how we keep your personal data secure within our Privacy Policy, which can be found at https://broadway-pharmacy.co.uk/privacy-notice/. Information on how our Website uses cookies can be found at https://broadway-pharmacy.co.uk/cookie-policy/.

3.2. We may also share any personal data that you provide to us in connection with the Service with:

(a) NHS England, to allow them to monitor our Service and to help evaluate the Service; and

(b) the NHS Business Services Authority and NHS England, to allow them to manage the contract we have with the NHS, to make sure we are paid correctly for the Service (by the NHS) and that we have provided the Service correctly.

4. ELIGIBILITY REQUIREMENTS AND REGISTRATION PROCEDURE

4.1. Our Website has a platform, on which you will be able to register for the Service.

4.2. In order to register for the Service, you must be:

(a) Registered with a General Practitioner practice in England or live in England and have a General Practitioner practice in one of the other home countries (Wales, Scotland or Northern Ireland); and

(b) eligible to receive the Service, namely that you have at least one risk factor for progression to severe Covid-19 (as set out in the “NICE Guidelines”, which are available at https://www.nice.org.uk/guidance/ta878/chapter/5-Supporting-information-on-risk-factors-for-progression-to-severe-COVID-19) or otherwise on request.

4.3. We are required to satisfy ourselves as to your eligibility to receive the Service. In order to do this, the Website contains a registration form (the “Registration Form”) which requires you to provide us with information including but not limited to:

(a) your date of birth;

(b) email address and/or telephone number;

(d) your General Practitioner’s details (including their name, the surgery name and postal address);

(e) any NHS letter from before 27 June 2023 confirming your eligibility;

(f) in the absence of any such NHS letter, confirmation that you have at least one risk factor for progression to severe Covid-19 according to the Nice Guidelines; and

(g) such other information that we may request that you provide when completing the Registration Form.

4.4. By completing the Registration Form and registering for the Service, you also confirm that we are authorised to review the National Care Records Service to satisfy ourselves as to your eligibility to receive the Service.

4.5. Once you have completed the Registration Form, we may contact you using the email address and/or telephone number you provide to us in order to obtain further information regarding your eligibility to receive the Service. At that time, we may request that you provide us with further documentation relating to your eligibility to receive the Service.

4.6. You confirm to us that the information that you provide to us relating to your eligibility to receive the Service (whether in the Registration Form or otherwise) will be true, complete and accurate. You acknowledge that we can have no liability to you whatsoever as a result of any incomplete, inaccurate and/or untrue information that you supply to us. For example, if you provide us with an incorrect Delivery Address, we cannot be responsible for any delivery of LFDs to that Delivery Address.

4.7. We reserve the right to refuse access to the Service to individuals that we reasonably consider are:

(a) not eligible to receive the Service;

(b) attempting to register for the Service on behalf of an individual that is not eligible to receive the Service;

(d) using the Service for fraudulent or other criminal activities,

and in each case we reserve the right to report such to the appropriate authorities.

4.8. If you experience any issues or have any questions during the initial registration process, please contact us under clause 1.3.

5. ONCE THE REGISTRATION PROCESS IS COMPLETED

5.1. Once you have completed our Registration Form and provided any additional information that we require in relation to your eligibility to receive the Service, we will review the details that you have provided and inform you as to whether you have been accepted as being eligible to receive the Service in writing or by telephone.

5.2. If we do not consider that you are eligible to receive the Service, we will notify you of this in writing or by telephone, explaining the reasons why.

6. DELIVERY OF THE LFDS

6.1. Any delivery of the LFDs to you in connection with the Service will be made via Royal Mail or any other courier of our choice.

6.2. Any delivery dates that we notify to you are approximate only and are subject to when the Royal Mail or our other couriers are able to deliver the LFDs. To the greatest extent permitted by law, we will not be responsible for any delays experienced with the delivery of the LFDs.

6.3. If you require urgent access to LFDs, please contact us and we will discuss the available options. An alternative course of action may also be to visit our pharmacy (see above our pharmacy address) or an alternative pharmacist.

6.4. If you fail to accept the delivery of your LFDs, or if you wish to change your Delivery Addressonce your LFDs have been processed for delivery, you must contact us and provide anyinformation required for us to process any further delivery or request. We reserve the right to reject any such request in the circumstances described in clause 4.7.

7. TESTING AND POSITIVE RESULTS

7.1. If you have any symptoms of Covid 19 (see https://www.nhs.uk/conditions/covid-19/covid-19-symptoms-and-what-to-do/ for a list of typical symptoms), you should take an LFD test as soon as possible, even if your symptoms are mild.

7.2. If you test positive, we recommend that you call either your General Practitioner, NHS 111 or another hospital specialist as soon as possible. NHS guidance regarding the steps you can take can also be found at https://www.nhs.uk/nhs-services/covid-19-services/testing-for-covid-19/test-results-for-covid-19-and-how-to-report-them/.

7.3. If you test negative, but still have symptoms of Covid-19, you should take a total of three LFDs over three consecutive days. If any of those tests are positive, you should carry out the actions set out in clause 7.2.

8. INFORMATION CONTAINED ON THE WEBSITE AND ADDITIONAL RESOURCES

8.1. We take care to ensure that the information on the Website relating to the Service and Covid-19 is accurate. However, this is an area that is continually developing and, occasionally, the information provided may be out of date. General medical information provided on the Website or in these Terms is for general purposes only and is not a substitute for specific medical advice which is tailored to any particular medical need.

8.2. Additional and lengthy resources relating to Covid-19 can be found via the NHS website at www.NHS.com, however this link and other links to websites which are controlled by third parties are for your convenience only and we have no control over any information contained on them or your use of them.

8.3. If you have a medical emergency, Covid-19 related or otherwise, please contact your General Practitioner or contact 111 or 999.

9. OUR LIABILITY TOWARDS YOU

9.1. We do not exclude or limit in any way its liability to you where it would be unlawful to do so. This includes liability for death or personal injury caused by our negligence or the negligence of our employees, agents or subcontractors; for fraud or fraudulent misrepresentation; for breach of your legal rights in respect of the Services.

9.2. To the greatest extent permissible by law, we will not be responsible for any:

(a) loss of profit;

(b) loss of goodwill;

(d) loss of business opportunity;

(e) loss of anticipated saving;

(f) loss or corruption of data or information; or

(g) any indirect, special or consequential loss,

that arises under or in connection with these Terms or your use of the Service, whether arising in contract, tort (including negligence) breach of statutory duty or otherwise.

9.3. We will also not be responsible for any loss or damage suffered by you as a consequence of any false, misleading or inaccurate information you provide to us in connection with the Service.

10. THIRD PARTY RIGHTS

These Terms do not give rise to any rights for any third party to enforce any term of these Terms.

11. EVENTS BEYOND OUR REASONABLE CONTROL

We will not be in breach of any of our obligations under these Terms (or otherwise liable for any failure or delay in performance) if we are prevented, hindered or delayed in or from performing any of our obligations by any event beyond our reasonable control. The time for performance of our obligations shall be extended accordingly, however if the delay continues, we will keep you informed.

12. VARIATION

We may change these Terms at any time. Please read these Terms every time you wish to use the Service, so that you’re aware of any changes we have made.

13. JURISDICTION AND APPLICABLE LAW

These Terms are governed by English law and any dispute arising under or in connection with them shall be determined exclusively by the English courts.

14. HOW TO MAKE A COMPLAINT

To make an official complaint about either the Website or the Service, you should contact the Customer Support management team. You can do this in any of the following ways:

(a) phone: 01772 717 574 (Monday to Friday 8:30am to 6pm, Saturday 8:30am to 17:00, Sunday – 10:00am to 13:00pm);

(b) email: contact@broadway-pharmacy.co.uk; and

Factsheet: Eligible patient groups for the LFD service

The National Institute for Health and Care Excellence (NICE) has published guidance which lists the risk factors for progression to severe COVID-19 in young people aged between 12 and 17 years and adults. These patients are therefore potentially eligible for COVID-19 treatments should they catch COVID-19 and are eligible to access free LFD test kits from community pharmacies under the NHS Lateral Flow Device tests supply service for patients potentially eligible for COVID-19 treatments (Advanced service) (the LFD service).

Risk factors for progression to severe COVID-19 in adults defined by the independent advisory group commissioned by the Department of Health and Social Care (June 2023)

Down's syndrome and other genetic disorders

All individuals with Down's syndrome or other chromosomal disorders known to affect immune competence

Solid cancer

▪ metastatic or locally advanced inoperable cancer

▪ lung cancer (at any stage)

▪ people receiving any chemotherapy (including antibody-drug conjugates), PI3K inhibitors or radiotherapy within 12 months

▪ people who have had cancer resected within 3 months and who received no adjuvant chemotherapy or radiotherapy

▪ people who have had cancer resected within 3 to 12 months and receiving no adjuvant chemotherapy or radiotherapy are expected to be at less risk (and thus less priority) but still at increased risk compared with the non-cancer populations

Haematological diseases and recipients of haematological stem cell transplant (HSCT)

▪ allogeneic HSCT recipients in the last 12 months or active graft versus host disease (GVHD) regardless of time from transplant (including HSCT for non-malignant diseases)

▪ autologous HSCT recipients in the last 12 months (including HSCT for non-malignant diseases)

▪ individuals with haematological malignancies who have received CAR-T cell therapy in the last

24 months, or until the lymphocyte count is within the normal range

▪ individuals with haematological malignancies receiving systemic anti-cancer treatment (SACT) within the last 12 months, or radiotherapy in the last 12 months

▪ all people who do not fit the criteria above, and are diagnosed with: o myeloma (excluding monoclonal gammopathy of undetermined significance [MGUS]) o AL amyloidosis

o chronic B-cell lymphoproliferative disorders (chronic lymphocytic leukaemia, follicular lymphoma)

o myelodysplastic syndrome (MDS) o chronic myelomonocytic leukaemia (CMML) o myelofibrosis

o any mature T-cell malignancy

▪ all people with sickle cell disease

▪ people with thalassaemia or rare inherited anaemia with any of the following:

o severe cardiac iron overload (T2 * less than 10 ms)

o severe to moderate iron overload (T2 * greater than or equal to 10 ms) plus an additional comorbidity of concern (for example, diabetes, chronic liver disease or severe hepatic iron load on MRI)

▪ individuals with non-malignant haematological disorders (for example, aplastic anaemia or paroxysmal nocturnal haemoglobinuria) receiving B-cell depleting systemic treatment (for example, anti-CD20, anti-thymocyte globulin [ATG] and alemtuzumab) within the last 12 months

Renal disease

▪ renal transplant recipients (including those with failed transplants within the past 12 months), particularly those who have:

o received B-cell depleting therapy within the past 12 months (including alemtuzumab, rituximab [anti-CD20], ATG)

o an additional substantial risk factor which would in isolation make them eligible for monoclonals or oral antivirals

▪ non-transplant renal patients who have received a comparable level of immunosuppression

▪ patients with chronic kidney disease (CKD) stage 4 or 5 (an estimated glomerular filtration rate

[eGFR] less than 30 ml per min per 1.73 m²) without immunosuppression

Liver diseases

▪ people with cirrhosis Child-Pugh (CP) class A, B and C, whether receiving immune suppressive therapy or not. Those with decompensated liver disease (CP B and C) are at greatest risk

▪ people with a liver transplant

▪ people with liver disease on immune suppressive therapy (including people with and without cirrhosis)

Solid organ transplant recipients

Solid organ transplant recipients not in any of the above categories

Immune-mediated inflammatory disorders (diseases in which autoimmune or

autoinflammation-based pathways are implicated in disease, for example, inflammatory arthritis, connective tissue diseases, inflammatory skin diseases, inflammatory gastrointestinal disease)

▪ people who have received a B-cell depleting therapy (anti-CD20 drug, for example, rituximab, ocrelizumab, ofatumab, obinutuzumab) in the last 12 months

▪ people who have been treated with cyclophosphamide (IV or oral) in the 6 months prior to positive PCR or relevant COVID test

▪ people who are on corticosteroids (equivalent to or greater than 10 mg per day of prednisolone) for at least the 28 days prior to positive PCR

▪ people who are on biologics or small molecule JAK inhibitors

▪ people who are on current treatment with mycophenolate mofetil, oral tacrolimus, azathioprine, mercaptopurine, or similar agents (for major organ involvement such as kidney, gastro-intestinal tract, liver, lung, brain), methotrexate (for interstitial lung disease or asthma only) and/or ciclosporin. No minimum dose threshold is suggested

▪ people who are on current treatment (or within the last 6 months) with S1P modulators

(fingolimod, ponesimod or siponimod), or alemtuzumab or cladribine within the last 12 months

▪ people who exhibit at least one of: (a) uncontrolled or clinically active disease (that is, required recent increase in dose or initiation of new immunosuppressive drug or IM steroid injection or course of oral steroids within the 3 months prior to positive PCR); and/or (b) other high risk comorbidities (for example, body mass index [BMI] greater than 30, diabetes mellitus, hypertension, major organ involvement such as significant kidney, liver, nervous system or lung inflammation or significantly impaired renal, liver, nervous system and/or lung function)

Respiratory ▪ asthma in people on oral corticosteroids (defined above). Any asthma patient taking immunosuppressants for their asthma including but not exclusively methotrexate, ciclosporin ▪ COPD on long term home non-invasive ventilation (NIV). Patients on long term oxygen therapy. People with moderate or severe disease (FEV1 less than or equal to 50% predicted) who have required 4 or more courses of prednisolone 30 mg for 5 days or greater in last 12 months ▪ interstitial lung disease (ILD) – all patients with idiopathic pulmonary fibrosis ▪ sub-types of ILD, for example, connective tissue disease related, sarcoidosis, hypersensitivity pneumonitis, NSIP (non-specific interstitial pneumonia) who have received a B-cell depleting therapy in last 12 months, or IV or oral cyclophosphamide in the 6 months prior to testing positive for COVID-19. Any ILD patient on current treatment with corticosteroids, mycophenolate mofetil, azathioprine, tacrolimus, cyclosporin or methotrexate. No minimum dose criteria ▪ any people with any type of ILD who may not be on treatment due to intolerance but has severe disease with an FVC predicted less than 60% ▪ NIV and tracheostomy ventilated – all patients requiring this type of support regardless of the underlying disorder (which might include COPD, obesity hypoventilation syndrome, scoliosis, bronchiectasis, neurodisability and genetic muscular diseases [refer to neurology section]). ▪ lung cancer patients, refer to 'Solid cancer' section above ▪ lung transplant patients (refer to solid organ transplant section) ▪ pulmonary hypertension (PH): groups 1 and 4 from PH classification Immune deficiencies ▪ common variable immunodeficiency (CVID) ▪ undefined primary antibody deficiency on immunoglobulin (or eligible for Ig) ▪ hyper-IgM syndromes ▪ Good's syndrome (thymoma plus B-cell deficiency) ▪ severe combined immunodeficiency (SCID) ▪ autoimmune polyglandular syndromes or autoimmune polyendocrinopathy, candidiasis, ectodermal dystrophy (APECED syndrome) ▪ primary immunodeficiency associated with impaired type 1 interferon signalling ▪ X-linked agammaglobulinaemia (and other primary agammaglobulinaemias) ▪ any person with secondary immunodeficiency receiving, or eligible for, immunoglobulin replacement therapy HIV/AIDS ▪ people with high levels of immune suppression, have uncontrolled or untreated HIV (high viral load) or present acutely with an AIDS defining diagnosis ▪ people on treatment for HIV with CD4 less than 350 cells per mm³ and stable on HIV treatment or CD4 greater than 350 cells per mm³ and additional risk factors (for example, age, diabetes, obesity, cardiovascular, liver or renal disease, homeless, alcoholic dependency) Neurological disorders ▪ Conditions associated with neuromuscular respiratory failure requiring chronic ventilatory support: o motor neurone disease o Duchenne muscular dystrophy ▪ Conditions that require use of specific immunotherapies: o multiple sclerosis (MS) o myasthenia gravis (MG) o other immune-mediated disorders ▪ Dementia, neurodegenerative and neuroimmune disorders when associated with severe frailty (for example, levels 7 or 8 on Clinical Frailty Scale, as part of a personalised care plan):
o	Alzheimer's disease, vascular disease, Lewy body disease, or frontotemporal atrophy
o	Parkinson's disease
o	Huntington's disease
o	progressive supranuclear palsy and multiple system atrophy
o	motor neurone disease
o	multiple sclerosis and other immune-mediated neurological disorders

Risk factors for progression to severe COVID-19 in young people aged 12 to 17 years
Pathway for PCR positive symptomatic cases aged older than 12 and younger than 18 years, greater than 40 kg weight, and clinical concern: defined by the independent advisory group commissioned by the Department of Health and Social Care (March 2023) Non-hospitalised individuals in the older than 12 and younger than 18 years age range considered at high risk from COVID-19 and to be prioritised for consideration of treatment with neutralising monoclonal antibodies when symptomatic and SARS-CoV-2 PCR positive. Concerned clinicians should refer for regional multidisciplinary team (MDT) case discussion through local established pathways, who will confirm eligibility and consider risk benefit and whether to proceed with offer of treatment. Children and young people (CYP) at substantial risk Complex life-limiting neurodisability with recurrent respiratory infections or compromise. CYP at significant risk if 2 or more of these risk factors are present Primary immunodeficiency: ▪ common variable immunodeficiency (CVID) ▪ primary antibody deficiency on immunoglobulin (or eligible for immunoglobulin replacement) ▪ hyper-IgM syndromes ▪ Good's syndrome (thymoma plus B-cell deficiency) ▪ severe combined immunodeficiency (SCID) ▪ autoimmune polyglandular syndromes or autoimmune polyendocrinopathy, candidiasis, ectodermal dystrophy (APECED syndrome) ▪ primary immunodeficiency associated with impaired type 1 interferon signalling ▪ X-linked agammaglobulinaemia (and other primary agammaglobulinaemias) Secondary immunodeficiency: ▪ HIV CD4 count less than 200 cells per mm³ ▪ solid organ transplant ▪ haematological stem cell transplant (HSCT) within 12 months, or with graft versus host disease (GVHD) ▪ CAR-T cell therapy in last 24 months ▪ induction chemotherapy for acute lymphoblastic leukaemia (ALL), non-Hodgkin's lymphoma, chemotherapy for acute myeloid leukaemia (AML), relapsed and/or refractory leukaemia or lymphoma Immunosuppressive treatment: ▪ chemotherapy within the last 3 months ▪ cyclophosphamide within the last 3 months ▪ corticosteroids greater than 2 mg per kg per day for 28 days in last 4 weeks ▪ B-cell depleting treatment in the last 12 months Other conditions: ▪ high body mass index (BMI; greater than 95th centile)
▪	severe respiratory disease (for example, cystic fibrosis or bronchiectasis with FEV1 less than 60%)
▪	tracheostomy or long-term ventilation
▪	severe asthma (paediatric intensive care unit [PICU] admission in 12 months)
▪	neurodisability and/or neurodevelopmental disorders
▪	severe cardiac disease
▪	severe chronic kidney disease
▪	severe liver disease
▪	sickle cell disease or other severe haemoglobinopathy
▪	trisomy 21
▪	complex or chromosomal genetic or metabolic conditions associated with significant comorbidity
▪	multiple congenital anomalies associated with significant comorbidity
▪	bronchopulmonary dysplasia – decisions should be made taking into account degree of prematurity at birth and chronological age
▪	infants less than 1 year with congenital heart disease (CHD): o cyanotic CHD o haemodynamically significant acyanotic CHD and history of prematurity o those due for corrective surgery, to avoid complications or delay due to SARS-CoV-2 infection

A trusted NHS partner providing FREE COVID-19 Lateral Flow Device Tests to those that need them* *Must meet eligibility criteria, view HERE

Complete the form to receive your FREE Covid test kit

Test yourself this autumn and winter period

Our Process

Three simple steps

Providing NHS COVID-19 & Flu vaccinations across the North West of England

Testimonial

What Our Patients Say

Matt Brett

Zach Khan

Nela k

Wendy Watt

Andrew Mortimer

Phone

Email

Location

A trusted NHS partner providing FREE COVID-19 Lateral Flow Device Tests to those that need them*
*Must meet eligibility criteria, view HERE

Three
simple steps

Providing NHS COVID-19 & Flu vaccinations
across the North West of England